Oculis S.A.

Oculis is a clinical stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases for both back- and front-of-the-eye in order to improve the lives of patients worldwide. INNOVATIVE TOPICAL THERAPIES FOR MILLIONS OF PATIENTS WORLDWIDE The Oculis strategy is to build a specialty ophthalmology company unlike any other. Our plan is to further advance our lead candidate, OC-118, for commercialisation as a new therapeutic option for DME patients and to develop a clinical pipeline of topical treatments for back- and front-of the-eye disease based on internal development with our proprietary SNP technology and via complementary in-licensed assets OC-118 A POTENTIAL PARADIGM SHIFT IN DME TREATMENT Our most advanced product candidate based on SNP technology is OC-118, which is in clinical trials in patients with DME and in planning phase for potential front-of-the-eye indications. If approved in DME, it has the potential to provide a new option for patients for whose current therapies are limited to intravitreal injections or implants. TAKING TREATMENT FROM INJECTIONS TO DROPS FOR BACK-OF-THE-EYE DISEASES Our novel technology provides an unprecedented technical advancement in ocular drug delivery, particularly for back-of-the-eye diseases that are currently managed by invasive methods such as intraocular injections or implants.